Contributions
Abstract: EP1373a
Type: ePoster
Abstract Category: Clinical aspects of MS - Epidemiology
Background and Goals: Multiple Sclerosis (MS) coexistence with other autoimmune diseases is not uncommon. We aimed to assess prevalence of autoimmune comorbidities in MS patients in Greece.
Methods: We included 973 Greek patients (327 men and 646 women) with clinical definite MS who were admitted to our Department between 2005 and 2014 and had complete medical and family history documented.
Results: The most prevalent comorbidities were Thyroiditis (Men N=11, 3.4%; Women N=132, 20.4%; Total N=143, 14.7%), Psoriasis (Men N=5, 1.5%; Women N=14, 2.2%; Total N=19, 1.9%), Inflammatory Bowel Disease (Men N=4, 1.2%; Women N=8, 1.2%; Total N=12, 1.23%) and Systemic Lupus Erythematosus (Men N=0, 0%; Women N=8, 0.8%; Total N=8, 0.8%). Other reviewed comorbidities, each of which had prevalence lower than 1%, included: Myasthenia Gravis, Rheumatoid Arthritis, Sjogren"s syndrome, Vitiligo and Raynaud"s syndrome. No correlation was observed between the number of coexisting autoimmune diseases and family history of MS. Positive family history of MS was reported in 6.2% (N=60) of our cohort. Among those, 61.7% (N=37) had a first-degree, 10% (N=6) a second-degree and 28.3% (N=17) a third-degree relative with MS.
Discussion: The mosaic of comorbidities observed in MS patients may reflect a extented disregulation of the autoimmune system with different patterns of clinical manifestations. Detailed documentation of comorbidities combined with genetic markers may help elucidate the pathogenesis of polyautoimmunity.
Disclosure: G. Koutsis has received research grants from Genesis Pharma and Teva, consultation fees, advisory board renumeration and honoraria from Genzyme, Genesis Pharma, Teva and Novartis.
M.E. Evangelopoulos has provided consultation services for and received honoraria from Novartis, Biogen and Teva.
M. Anagnostouli has received research grants from Biogen, Merck-Serono, Novartis, Teva, Bayer and Genzyme, as well as lecture fees from Novartis, Teva, Biogen and Genzyme.
E. Andreadou has received research grants from Biogen, Merck-Serono, Novartis, and Sanofi Aventis, as well as lecture fees from Teva.
C. Kilidireas has received grants and honoraria from: Bayer, Biogen, Genesis Pharma, Merck-Serono, Novartis, Sanofi - Genzyme, Teva.
Abstract: EP1373a
Type: ePoster
Abstract Category: Clinical aspects of MS - Epidemiology
Background and Goals: Multiple Sclerosis (MS) coexistence with other autoimmune diseases is not uncommon. We aimed to assess prevalence of autoimmune comorbidities in MS patients in Greece.
Methods: We included 973 Greek patients (327 men and 646 women) with clinical definite MS who were admitted to our Department between 2005 and 2014 and had complete medical and family history documented.
Results: The most prevalent comorbidities were Thyroiditis (Men N=11, 3.4%; Women N=132, 20.4%; Total N=143, 14.7%), Psoriasis (Men N=5, 1.5%; Women N=14, 2.2%; Total N=19, 1.9%), Inflammatory Bowel Disease (Men N=4, 1.2%; Women N=8, 1.2%; Total N=12, 1.23%) and Systemic Lupus Erythematosus (Men N=0, 0%; Women N=8, 0.8%; Total N=8, 0.8%). Other reviewed comorbidities, each of which had prevalence lower than 1%, included: Myasthenia Gravis, Rheumatoid Arthritis, Sjogren"s syndrome, Vitiligo and Raynaud"s syndrome. No correlation was observed between the number of coexisting autoimmune diseases and family history of MS. Positive family history of MS was reported in 6.2% (N=60) of our cohort. Among those, 61.7% (N=37) had a first-degree, 10% (N=6) a second-degree and 28.3% (N=17) a third-degree relative with MS.
Discussion: The mosaic of comorbidities observed in MS patients may reflect a extented disregulation of the autoimmune system with different patterns of clinical manifestations. Detailed documentation of comorbidities combined with genetic markers may help elucidate the pathogenesis of polyautoimmunity.
Disclosure: G. Koutsis has received research grants from Genesis Pharma and Teva, consultation fees, advisory board renumeration and honoraria from Genzyme, Genesis Pharma, Teva and Novartis.
M.E. Evangelopoulos has provided consultation services for and received honoraria from Novartis, Biogen and Teva.
M. Anagnostouli has received research grants from Biogen, Merck-Serono, Novartis, Teva, Bayer and Genzyme, as well as lecture fees from Novartis, Teva, Biogen and Genzyme.
E. Andreadou has received research grants from Biogen, Merck-Serono, Novartis, and Sanofi Aventis, as well as lecture fees from Teva.
C. Kilidireas has received grants and honoraria from: Bayer, Biogen, Genesis Pharma, Merck-Serono, Novartis, Sanofi - Genzyme, Teva.